GoKawiilPLA2G2D enzyme in lymph nodes found to suppress anti-tumor immune response
Researchers analyzed tumor-draining lymph nodes from melanoma and non-small cell lung cancer patients, comparing those with early disease recurrence to those without, using tissue collected during routine diagnostic procedures at Erasmus MC. The study identifies the enzyme PLA2G2D as a regulator within these lymph nodes that influences how effectively the immune system mounts a response against tumors.
GoKawiil's interpretation of the reporting above, not reported fact.
Tumor-draining lymph nodes act as staging grounds for anti-tumor immunity, and understanding molecular brakes like PLA2G2D could reveal why some patients relapse despite seemingly localized disease. This finding could point toward new biomarkers for recurrence risk or targets to enhance immunotherapy by reversing immune suppression at the lymph node level before cancer spreads.
- PLA2G2D was identified as a regulator of anti-tumor immune activity within tumor-draining lymph nodes.
- The study used retrospective tissue samples from melanoma and NSCLC patients treated without immunotherapy, isolating the lymph node's natural immune role.
- Findings could inform future strategies to predict or prevent cancer recurrence by targeting lymph node immune regulation.
Source: nature.com — Van Krimpen, 2026-09-09
Published there as: “PLA2G2D in tumour-draining lymph nodes regulates anti-tumour immunity”
Read the original report → The summary and analysis above are GoKawiil's own, written from reporting by the source above. Facts and quotes belong to the original publisher.